This Article Full Text Full Text (PDF) View Correction Correction (v48,p2610) All Versions of this Article: j.jacc.2006.09.004v1 48/7/1498    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by Davis, M. M. Articles by Krumholz, H. M. Search for Related Content PubMed PubMed Citation Articles by Davis, M. M. Articles by Krumholz, H. M.

AHA/ACC SCIENCE ADVISORY

Influenza Vaccination as Secondary Prevention for Cardiovascular Disease

A Science Advisory From the American Heart Association/American College of Cardiology

ABSTRACT: Evidence from cohort studies and a randomized clinical trial indicates that annual vaccination against seasonal influenza prevents cardiovascular morbidity and all-cause mortality in patients with cardiovascular conditions. The American Heart Association and American College of Cardiology recommend influenza immunization with inactivated vaccine (administered intramuscularly) as part of comprehensive secondary prevention in persons with coronary and other atherosclerotic vascular disease (Class I, Level B). Immunization with live, attenuated vaccine (administered intranasally) is contraindicated for persons with cardiovascular conditions. It is important to note that influenza vaccination coverage levels overall and in this population remain well below national goals and are marked by disparities across different age and ethnic groups. One of the barriers to vaccination for patients with cardiovascular disease is that cardiology practices frequently do not stock and administer influenza vaccine. Healthcare providers who treat individuals with cardiovascular disease can help improve influenza vaccination coverage rates by providing and strongly recommending vaccination to their patients before and throughout the influenza season.

Key Words: AHA Scientific Statements • cardiovascular diseases • influenza, human • influenza vaccines

This article has been cited by other articles:

				S. W. Casscells, E. Granger, A. M. Kress, A. Linton, M. Madjid, and L. Cottrell Use of Oseltamivir After Influenza Infection Is Associated With Reduced Incidence of Recurrent Adverse Cardiovascular Outcomes Among Military Health System Beneficiaries With Prior Cardiovascular Diseases Circ Cardiovasc Qual Outcomes, March 1, 2009; 2(2): 108 - 115. [Abstract] [Full Text] [PDF]

				A. G. S. C. Jansen, E. A. M. Sanders, A. W. Hoes, A. M. van Loon, and E. Hak Influenza- and respiratory syncytial virus-associated mortality and hospitalisations Eur. Respir. J., December 1, 2007; 30(6): 1158 - 1166. [Abstract] [Full Text] [PDF]

				Offer Flu Vaccine in Your Cardiology Practice Journal Watch Cardiology, October 11, 2006; 2006(1011): 1 - 1. [Full Text]